Key learning objectives
- To understand the role of the incretin hormones, native GLP-1 and GIP, in humans
- To discuss the effects of incretin-based therapy in people with T2D and its position in the treatment pathway
- To review important considerations of risk management in diabetes
Speakers:
- Louise Dodd, Medical education associate, Lilly
- Dr Mike Pieredes, Specialist consultant, Northampton
Your contact details will be shared with Lilly.